LifeArc played an important part in the discovery of lecanemab, an experimental drug that has shown some benefits for people with early Alzheimer’s disease.
The findings reveal that seemingly impossible chemical reactions can be driven through a phenomenon called quantum tunnelling.
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS
Researchers can now apply for funding to progress exciting gene therapy research.
The toolkit helps researchers, charities and others navigate the opportunities and challenges of repurposing medicines.
LifeArc scientist Finbar Gaffey awarded a coveted industrial fellowship from the Royal Commission for the Exhibition of 1851.
It is with deep sadness that we share the news that Aisling Burnand CBE passed away on Monday 19 September 2022.
LifeArc's Chief Scientific Officer calls for UK science to continue to be a contributor to the Horizon Europe programme.
Melanie Lee talks about LifeArc’s commitment to patients, and explains why we should all care about science translation.